Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials

Seshasai, S.R.K., Bennett, R.L., Petrie, J.R. , Bengus, M., Ekman, S., Dixon, M., Herz, M., Buse, J.B. and Ray, K.K. (2015) Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 17(5), pp. 505-510. (doi: 10.1111/dom.12448) (PMID:25656522)

Full text not currently available from Enlighten.

Abstract

Aims: To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide.<p></p> Methods: We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type 2 diabetes. Our primary outcome was a composite of death from cardiovascular disease (CVD) and acute myocardial infarction, stroke and hospitalization for unstable angina.<p></p> Results: Overall, 7056 individuals were included in the analysis, and there were 67 primary endpoint events during 7478 person-years of follow-up (40 vs 27 events in the intervention vs control groups, respectively). The odds ratio for the composite endpoint among people randomized to taspoglutide was 0.94 (95% confidence interval 0.57–1.56), which was robust across multiple subgroups. Longer-term data were not available as the development of taspoglutide was stopped because of gastrointestinal intolerance and serious hypersensitivity reactions.<p></p> Conclusions: The available data suggest that short-term, once-weekly administration of taspoglutide was not associated with an excess risk of CVD, and provide insights relevant to the development of other novel once-weekly incretin mimetics.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Petrie, Professor John
Authors: Seshasai, S.R.K., Bennett, R.L., Petrie, J.R., Bengus, M., Ekman, S., Dixon, M., Herz, M., Buse, J.B., and Ray, K.K.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Diabetes, Obesity and Metabolism
Publisher:John Wiley & Sons Ltd.
ISSN:1462-8902
ISSN (Online):1463-1326

University Staff: Request a correction | Enlighten Editors: Update this record